Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥ 10

Simple item page
dc.contributor.authorWainberg, Zev A.
dc.contributor.authorFuchs, Charles S.
dc.contributor.authorTabernero, Josep
dc.contributor.authorShitara, Kohei
dc.contributor.authorMuro, Kei
dc.contributor.authorVan Cutsem, Eric
dc.contributor.authorBang, Yung-Jue
dc.contributor.authorChung, Hyun Cheol
dc.contributor.authorYamaguchi, Kensei
dc.contributor.authorVarga, Eniko
dc.contributor.authorChen, Jen-Shi
dc.contributor.authorHochhauser, Daniel
dc.contributor.authorThuss-Patience, Peter
dc.contributor.authorAl-Batran, Salah-Eddin
dc.contributor.authorGarrido, Marcelo
dc.contributor.authorKher, Uma
dc.contributor.authorShih, Chie-Schin
dc.contributor.authorShah, Sukrut
dc.contributor.authorBhagia, Pooja
dc.contributor.authorChao, Joseph
dc.date.accessioned2025-01-20T23:52:04Z
dc.date.available2025-01-20T23:52:04Z
dc.date.issued2021
dc.description.abstractPurpose: Pembrolizumab demonstrated efficacy in PD-L1-positive [combined positive score (CPS) >= 1] advanced gastric/gastro-esophageal junction (G/GEJ) cancer in the first-, second-, and third-line setting in KEYNOTE-062, KEYNOTE-061, and KEYNOTE-059, respectively. To better delineate the specificity of CPS as a predictor of dinical outcomes, we analyzed pembrolizumab efficacy in patients with CPS >= 10 in these trials.
dc.description.abstractPatients and Methods: Included were patients with CPS >= 10 tumors from KEYNOTE-059 cohort I (pembrolizumab, n = 46; post hoc), KEYNOTE-061 (pembrolizumab, n = 53; chemotherapy, n = 55; post hoc), and KEYNOTE-062 (pembrolizumab, n = 92; chemotherapy, n = 90; primary). Efficacy outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR).
dc.description.abstractResults: In KEYNOTE-059, median follow-up was 6 months, median OS was 8 months [95% confidence interval (CI), 5.8-11.1], ORR was 17%, and median (range) DOR was 21 months (3+ to 35+). In KEYNOTE-061, median follow-up was 9 months, median OS (pembrolizumab vs. chemotherapy) was 10 versus 8 months (HR, 0.64; 95% CI, 0.41-1.02), median PFS was 3 months versus 3 months (HR, 0.86; 95% CI, 056-1.33), ORR was 25% versus 9%, and median (range) DOR was not reached (4 to 26+ months) versus 7 months (3-7). In KEYNOTE-062, median follow-up was 11 months, median OS (pembrolizumab vs. chemotherapy) was 17 months versus 11 months (HR, 0.69; 95% CI, 0.49-0.97), median PFS was 3 months versus 6 months (HR, 1.09, 95% CI; 0.79-1.49), ORR was 25% versus 38%, and median (range) DOR was 19 months (1+ to 34+) versus 7 months (2+ to 30+).
dc.description.abstractConclusions: This comprehensive analysis showed consistent improvements toward more favorable clinical outcomes with pembrolizumab across lines of therapy in patients with CPS >= 10 G/GEJ cancer.
dc.description.funderMerck Sharp Dohme Corp.
dc.fuente.origenWOS
dc.identifier.doi10.1158/1078-0432.CCR-20-2980
dc.identifier.eissn1557-3265
dc.identifier.issn1078-0432
dc.identifier.urihttps://doi.org/10.1158/1078-0432.CCR-20-2980
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/94880
dc.identifier.wosidWOS:000636977600014
dc.issue.numero7
dc.language.isoen
dc.pagina.final1931
dc.pagina.inicio1923
dc.revistaClinical cancer research
dc.rightsacceso restringido
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleEfficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥ 10
dc.typeartículo
dc.volumen27
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas